You are here

Article Text

Article menu

other Versions

Download PDFPDF
Prevention
Systematic review and meta-analysis
Cardiovascular benefits of HRT may differ by patient age
  1. Giuseppe Rosano,
  2. Cristiana Vitale
  1. Department of Medical Sciences, IRCCS San Raffaele, Rome, Italy
  1. Correspondence to: Professor Giuseppe Rosano, Department of Medical Sciences, IRCCS San Raffaele, Via della Pisana 235, Rome 00163, Italy; giuseppe.rosano{at}sanraffaele.it

https://doi.org/10.1136/eb-2013-101430

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Main C, Knight B, Moxham T, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2013;(4):CD002229OpenUrlPubMed.

    Context

    In early postmenopausal women oestrogen and/or hormone replacement therapy (ERT/HRT) are used to alleviate symptoms and reduce the probability of diseases related to ovarian hormones deprivation. However, in late postmenopausal women the initiation of HRT has a negative risk/benefit balance mainly because of the increased risk of cardiovascular diseases (CVD).

    Methods

    Main et al performed a meta-analysis of randomised controlled trials (RCTs) comparing oral ERT/HRT with either a placebo or a no-treatment control for 6 months or longer. Included in the analysis were those women with the evidence of being menopausal either with or without evidence of existing CVD.

    Two authors assessed study quality and extracted data from those references …

    View Full Text

    Footnotes

    • Competing interests None.